相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
Unknown
2
100.0%
暂无批准数据
- The FDA issued a warning letter to Fresenius Medical Care North America's Ogden, Utah facility on August 25, 2026, citing significant cGMP violations under 21 CFR Parts 210 and 211. - The most serious finding involved leaking Delflex Peritoneal Dialysis Solution bags, with 35 complaints covering about 156 bags from multiple batches attributed to holes caused by printing. - Fresenius assigned the lowest severity level to the leaks despite its own risk matrix identifying peritonitis as a potential harm, exposing patients to non-sterile products and potentially life-threatening complications. - The FDA has demanded an independent root-cause assessment and warned that inadequate correction could lead to seizure, injunction, or further regulatory action.
- Clinical research site performance is driven more by operating model than by traditional metrics like site count, investigator numbers, or therapeutic area coverage. - Freestanding research clinics offer strong operational control and faster start-up, with median activation of 4.37 months versus 8.12 months for academic medical centers. - Embedded private-practice sites provide superior patient access through treating physician relationships, while contracted PIs can create bottlenecks without adequate operating support. - A centrally governed hybrid model combining freestanding clinics with embedded private-practice operations may offer the optimal balance of access, control, speed, quality, and scalability.
- CerraCap Ventures has invested in Nephronomics, an AI-bio precision medicine company building the world's most comprehensive cardio-kidney-metabolic disease dataset with over 42,000 patients. - Nephronomics leverages exclusive access to the largest global renal dataset spanning U.S. dialysis clinics to identify new disease subtypes and develop novel therapeutic targets using advanced machine learning. - The platform aims to shift kidney disease drug discovery from correlation to causation, addressing a significant unmet need in chronic kidney disease affecting 14% of the U.S. population and 850 million people globally. - The company plans to develop internal therapeutic programs while partnering with pharmaceutical companies to accelerate precision medicine approaches in the under-researched kidney disease space.
- Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences have formed a strategic collaboration to advance genomic analysis of Frenova's My Reason® genomics research program. - The My Reason® program has registered over 35,000 participants with biospecimens, aiming to reach 50,000 participants over the next two years to build the world's most comprehensive kidney disease database. - The collaboration will leverage whole genome sequencing and AI/machine learning models to identify novel disease subtypes, protective genetic variants, and therapeutic targets for cardio-kidney-metabolic diseases. - GENEWIZ will provide DNA sequencing technologies and long-term sample storage through Azenta's global biorepository network to extract insights from the genomic and clinical data registry.
- Fresenius Medical Care received FDA 510(k) clearance for its enhanced 5008X CAREsystem, enabling broader U.S. commercialization of high-volume hemodiafiltration therapy. - The CONVINCE study demonstrated a 23% reduction in mortality rates for patients receiving high-volume hemodiafiltration compared to traditional high-flux hemodialysis. - The company will begin offering the therapy in selected Fresenius Kidney Care clinics throughout 2025, with full commercial launch planned for 2026. - The updated system includes Fresenius Clinical Data Exchange technology for improved workflow and reduced equipment clutter at chairside.
